Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms

M. Di Stefano, A. Strocchi, S. Malservisi, G. Veneto, A. Ferrieri, G. R. Corazza

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Background: Simethicone, activated charcoal and antimicrobial drugs have been used to treat gas-related symptoms with conflicting results. Methods. To study the relationship between gaseous symptoms and colonic gas production and to test the efficacy of rifaximin, a new non-absorbable antimicrobial agent, on these symptoms. Methods: Intestinal gas production was measured by hydrogen (H2) and methane (CH4) breath testing after lactulose in 21 healthy volunteers and 34 functional patients. Only the 34 functional patients took part in a double-blind, double-dummy controlled trial, receiving, at random, rifaximin (400 mg b.d per 7 days), or activated charcoal (400 mg b.d per 7 days). The following parameters were evaluated at the start of the study and 1 and 10 days after therapy: bloating, abdominal pain, number of flatus episodes, abdominal girth, and cumulative breath H2 excretion. Results: Hydrogen excretion was greater in functional patients than in healthy volunteers. Rifaximin, but not activated charcoal, led to a significant reduction in H2 excretion and overall severity of symptoms. In particular, in patients treated with rifaximin, a significant reduction in the mean number of flatus episodes and of mean abdominal girth was evident. Conclusions: In patients with gas-related symptoms the colonic production of H2 is increased. Rifaximin significantly reduces this production and the excessive number of flatus episodes.

Original languageEnglish
Pages (from-to)1001-1008
Number of pages8
JournalAlimentary Pharmacology and Therapeutics
Volume14
Issue number8
DOIs
Publication statusPublished - 2000

Fingerprint

rifaximin
Flatulence
Gases
Anti-Bacterial Agents
Charcoal
Simethicone
Hydrogen
Healthy Volunteers
Lactulose
Methane
Anti-Infective Agents
Abdominal Pain
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms. / Di Stefano, M.; Strocchi, A.; Malservisi, S.; Veneto, G.; Ferrieri, A.; Corazza, G. R.

In: Alimentary Pharmacology and Therapeutics, Vol. 14, No. 8, 2000, p. 1001-1008.

Research output: Contribution to journalArticle

Di Stefano, M. ; Strocchi, A. ; Malservisi, S. ; Veneto, G. ; Ferrieri, A. ; Corazza, G. R. / Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms. In: Alimentary Pharmacology and Therapeutics. 2000 ; Vol. 14, No. 8. pp. 1001-1008.
@article{00335000a82c4aada5ea338d0285adbd,
title = "Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms",
abstract = "Background: Simethicone, activated charcoal and antimicrobial drugs have been used to treat gas-related symptoms with conflicting results. Methods. To study the relationship between gaseous symptoms and colonic gas production and to test the efficacy of rifaximin, a new non-absorbable antimicrobial agent, on these symptoms. Methods: Intestinal gas production was measured by hydrogen (H2) and methane (CH4) breath testing after lactulose in 21 healthy volunteers and 34 functional patients. Only the 34 functional patients took part in a double-blind, double-dummy controlled trial, receiving, at random, rifaximin (400 mg b.d per 7 days), or activated charcoal (400 mg b.d per 7 days). The following parameters were evaluated at the start of the study and 1 and 10 days after therapy: bloating, abdominal pain, number of flatus episodes, abdominal girth, and cumulative breath H2 excretion. Results: Hydrogen excretion was greater in functional patients than in healthy volunteers. Rifaximin, but not activated charcoal, led to a significant reduction in H2 excretion and overall severity of symptoms. In particular, in patients treated with rifaximin, a significant reduction in the mean number of flatus episodes and of mean abdominal girth was evident. Conclusions: In patients with gas-related symptoms the colonic production of H2 is increased. Rifaximin significantly reduces this production and the excessive number of flatus episodes.",
author = "{Di Stefano}, M. and A. Strocchi and S. Malservisi and G. Veneto and A. Ferrieri and Corazza, {G. R.}",
year = "2000",
doi = "10.1046/j.1365-2036.2000.00808.x",
language = "English",
volume = "14",
pages = "1001--1008",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "8",

}

TY - JOUR

T1 - Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms

AU - Di Stefano, M.

AU - Strocchi, A.

AU - Malservisi, S.

AU - Veneto, G.

AU - Ferrieri, A.

AU - Corazza, G. R.

PY - 2000

Y1 - 2000

N2 - Background: Simethicone, activated charcoal and antimicrobial drugs have been used to treat gas-related symptoms with conflicting results. Methods. To study the relationship between gaseous symptoms and colonic gas production and to test the efficacy of rifaximin, a new non-absorbable antimicrobial agent, on these symptoms. Methods: Intestinal gas production was measured by hydrogen (H2) and methane (CH4) breath testing after lactulose in 21 healthy volunteers and 34 functional patients. Only the 34 functional patients took part in a double-blind, double-dummy controlled trial, receiving, at random, rifaximin (400 mg b.d per 7 days), or activated charcoal (400 mg b.d per 7 days). The following parameters were evaluated at the start of the study and 1 and 10 days after therapy: bloating, abdominal pain, number of flatus episodes, abdominal girth, and cumulative breath H2 excretion. Results: Hydrogen excretion was greater in functional patients than in healthy volunteers. Rifaximin, but not activated charcoal, led to a significant reduction in H2 excretion and overall severity of symptoms. In particular, in patients treated with rifaximin, a significant reduction in the mean number of flatus episodes and of mean abdominal girth was evident. Conclusions: In patients with gas-related symptoms the colonic production of H2 is increased. Rifaximin significantly reduces this production and the excessive number of flatus episodes.

AB - Background: Simethicone, activated charcoal and antimicrobial drugs have been used to treat gas-related symptoms with conflicting results. Methods. To study the relationship between gaseous symptoms and colonic gas production and to test the efficacy of rifaximin, a new non-absorbable antimicrobial agent, on these symptoms. Methods: Intestinal gas production was measured by hydrogen (H2) and methane (CH4) breath testing after lactulose in 21 healthy volunteers and 34 functional patients. Only the 34 functional patients took part in a double-blind, double-dummy controlled trial, receiving, at random, rifaximin (400 mg b.d per 7 days), or activated charcoal (400 mg b.d per 7 days). The following parameters were evaluated at the start of the study and 1 and 10 days after therapy: bloating, abdominal pain, number of flatus episodes, abdominal girth, and cumulative breath H2 excretion. Results: Hydrogen excretion was greater in functional patients than in healthy volunteers. Rifaximin, but not activated charcoal, led to a significant reduction in H2 excretion and overall severity of symptoms. In particular, in patients treated with rifaximin, a significant reduction in the mean number of flatus episodes and of mean abdominal girth was evident. Conclusions: In patients with gas-related symptoms the colonic production of H2 is increased. Rifaximin significantly reduces this production and the excessive number of flatus episodes.

UR - http://www.scopus.com/inward/record.url?scp=0033854244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033854244&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2036.2000.00808.x

DO - 10.1046/j.1365-2036.2000.00808.x

M3 - Article

VL - 14

SP - 1001

EP - 1008

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 8

ER -